Regencell Bioscience's 15min chart triggers bullish trend with Bollinger Bands expanding upward.

Regencell Bioscience's 15-minute chart has triggered Bollinger Bands Expanding Upward, a bullish indicator, as well as a Bullish Marubozu candlestick pattern at 10/06/2025 10:45. This suggests that the market trend is being driven by buyers, indicating strong purchasing pressure and a high likelihood of continued bullish momentum.

Regencell Bioscience Holdings Limited (NASDAQ: RGC), a Hong Kong-based biopharmaceutical company developing Traditional Chinese Medicine (TCM) treatments for neurocognitive disorders such as ADHD and autism spectrum disorder (ASD), has seen a significant bullish signal in its 15-minute chart. The chart has triggered Bollinger Bands Expanding Upward, a bullish indicator, as well as a Bullish Marubozu candlestick pattern at 10/06/2025 10:45. This suggests that the market trend is being driven by buyers, indicating strong purchasing pressure and a high likelihood of continued bullish momentum Regencell Bioscience Holdings Limited (RGC) Added to S&P Global BMI Index Amid Positive ADHD/ASD Trial Results^[1].

The Bollinger Bands Expanding Upward and the Bullish Marubozu candlestick pattern are technical indicators that often signal a potential upward trend. The Bollinger Bands expanding upward indicates that the price volatility is increasing, which can be a sign of strong buying pressure. The Bullish Marubozu candlestick pattern, characterized by a large body with no shadows, suggests a strong buying pressure that pushed the price up significantly.

Regencell Bioscience's stock has been highly volatile, with significant gains and losses throughout 2025. The company reported positive results from its second efficacy trial, showing a mean symptom improvement of 37% with no adverse side effects. However, it remains investigational, and no FDA-approved products have been announced yet. The stock experienced extreme volatility, peaking with an approximate 14,899% year-to-date gain by June, driven by speculative trading, a stock split, and excitement over trial results. Following this peak, shares saw sharp intra-day swings and a pullback, though technical indicators in September suggest a potential upward trend, supported by positive momentum and movement above its 50-day moving average Regencell Bioscience Holdings Limited (RGC) Added to S&P Global BMI Index Amid Positive ADHD/ASD Trial Results^[1].

Regencell Bioscience's inclusion in the S&P Global BMI Index on September 21, 2025, may enhance liquidity and help stabilize the stock, which has been highly volatile. Despite the progress, the business continues to face fundamental challenges, including zero revenue, ongoing losses, and uncertain regulatory pathways for its treatments. However, the positive clinical results and the recent technical indicators suggest a potential upward trend for the stock.

Investors should be cautious and conduct thorough research before making any investment decisions. The stock's extreme volatility and the company's ongoing challenges should be carefully considered. While the recent technical indicators suggest a potential upward trend, the stock's long-term performance will depend on various factors, including regulatory approvals, clinical trial results, and market conditions.